Synthesis and biological evaluation of novel naproxen–phenacetin triazole hybrids as promising anti-inflammatory agents with enhanced gastrointestinal tolerability
Ahmet Avci , Hayrünnisa Taşci , Begüm Nurpelin Sağlık Özkan , Gokcen Telli , Nesrin Gökhan-Kelekçi , Yusuf Özkay , Birsen Tozkoparan
{"title":"Synthesis and biological evaluation of novel naproxen–phenacetin triazole hybrids as promising anti-inflammatory agents with enhanced gastrointestinal tolerability","authors":"Ahmet Avci , Hayrünnisa Taşci , Begüm Nurpelin Sağlık Özkan , Gokcen Telli , Nesrin Gökhan-Kelekçi , Yusuf Özkay , Birsen Tozkoparan","doi":"10.1016/j.bioorg.2025.109000","DOIUrl":null,"url":null,"abstract":"<div><div>Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both COX-1 and COX-2 isoforms with limited selectivity, often resulting in gastrointestinal (GI) side effects. Compounds that preferentially inhibit COX-2 over COX-1 are believed to pose a lower ulcerogenic risk. To develop GI-safer and cost-effective anti-inflammatory agents, we designed hybrid molecules by combining naproxen and phenacetin with a 1,2,4-triazole-5-thione. The structures of synthesized compounds were confirmed <em>via</em> IR, <sup>1</sup>H/<sup>13</sup>C NMR, and HR-ESI-MS analyses. Among the compounds, ten inhibited COX-2 with IC₅₀ ≤ 0.56 μM, and five exhibited high selectivity (SI ≥ 100). Compounds <strong>46</strong> (IC₅₀ = 0.16 μM, SI = 2.36), <strong>55</strong> (0.19 μM, SI = 2.27), and <strong>59</strong> (0.21 μM, SI = 1.65) demonstrated potency comparable to celecoxib. Three selected compounds were further evaluated <em>in vivo</em> using a carrageenan-induced paw oedema model and for acute gastric toxicity in Swiss mouse (<em>n</em> = 6; Ethics No. 2024/11 08). Orally administered compounds <strong>55</strong> and <strong>64</strong> (20 mg/kg) reduced paw oedema by 61 % and 52 %, respectively, similar to indomethacin (52 %), without causing visible gastric lesions (lesion score ∼ 2 <em>vs.</em> 5 for indomethacin). Molecular docking studies of the active compounds revealed the formation of stable hydrogen bonds with His90 and Arg513 within the COX-2 side pocket, similar to the binding pattern observed in selective COX-2 inhibitors. <em>In silico</em> ADME assessments <em>via</em> SwissADME and PreADMET indicated that these compounds meet Lipinski's rule of five criteria, possess optimal polar surface area and Caco-2 permeability, and show minimal risk for local gastric irritation, suggesting promising oral bioavailability. Overall, the 1,2,4-triazole-thione–naproxen/phenacetin hybrids represent promising lead candidates for the development of GI-safer NSAIDs. Compounds <strong>55</strong> and <strong>64</strong>, in particular, merit further optimization and long-term safety evaluation.</div></div>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"165 ","pages":"Article 109000"},"PeriodicalIF":4.7000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic Chemistry","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0045206825008806","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both COX-1 and COX-2 isoforms with limited selectivity, often resulting in gastrointestinal (GI) side effects. Compounds that preferentially inhibit COX-2 over COX-1 are believed to pose a lower ulcerogenic risk. To develop GI-safer and cost-effective anti-inflammatory agents, we designed hybrid molecules by combining naproxen and phenacetin with a 1,2,4-triazole-5-thione. The structures of synthesized compounds were confirmed via IR, 1H/13C NMR, and HR-ESI-MS analyses. Among the compounds, ten inhibited COX-2 with IC₅₀ ≤ 0.56 μM, and five exhibited high selectivity (SI ≥ 100). Compounds 46 (IC₅₀ = 0.16 μM, SI = 2.36), 55 (0.19 μM, SI = 2.27), and 59 (0.21 μM, SI = 1.65) demonstrated potency comparable to celecoxib. Three selected compounds were further evaluated in vivo using a carrageenan-induced paw oedema model and for acute gastric toxicity in Swiss mouse (n = 6; Ethics No. 2024/11 08). Orally administered compounds 55 and 64 (20 mg/kg) reduced paw oedema by 61 % and 52 %, respectively, similar to indomethacin (52 %), without causing visible gastric lesions (lesion score ∼ 2 vs. 5 for indomethacin). Molecular docking studies of the active compounds revealed the formation of stable hydrogen bonds with His90 and Arg513 within the COX-2 side pocket, similar to the binding pattern observed in selective COX-2 inhibitors. In silico ADME assessments via SwissADME and PreADMET indicated that these compounds meet Lipinski's rule of five criteria, possess optimal polar surface area and Caco-2 permeability, and show minimal risk for local gastric irritation, suggesting promising oral bioavailability. Overall, the 1,2,4-triazole-thione–naproxen/phenacetin hybrids represent promising lead candidates for the development of GI-safer NSAIDs. Compounds 55 and 64, in particular, merit further optimization and long-term safety evaluation.
期刊介绍:
Bioorganic Chemistry publishes research that addresses biological questions at the molecular level, using organic chemistry and principles of physical organic chemistry. The scope of the journal covers a range of topics at the organic chemistry-biology interface, including: enzyme catalysis, biotransformation and enzyme inhibition; nucleic acids chemistry; medicinal chemistry; natural product chemistry, natural product synthesis and natural product biosynthesis; antimicrobial agents; lipid and peptide chemistry; biophysical chemistry; biological probes; bio-orthogonal chemistry and biomimetic chemistry.
For manuscripts dealing with synthetic bioactive compounds, the Journal requires that the molecular target of the compounds described must be known, and must be demonstrated experimentally in the manuscript. For studies involving natural products, if the molecular target is unknown, some data beyond simple cell-based toxicity studies to provide insight into the mechanism of action is required. Studies supported by molecular docking are welcome, but must be supported by experimental data. The Journal does not consider manuscripts that are purely theoretical or computational in nature.
The Journal publishes regular articles, short communications and reviews. Reviews are normally invited by Editors or Editorial Board members. Authors of unsolicited reviews should first contact an Editor or Editorial Board member to determine whether the proposed article is within the scope of the Journal.